Cara Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CARA and buy or sell other stocks, ETFs, and their options commission-free!About CARA
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.
CEOImran Alibhai, PhD
CEOImran Alibhai, PhD
Employees10
Employees10
HeadquartersSugar Land, Texas
HeadquartersSugar Land, Texas
Founded
Founded
Employees10
Employees10
CARA Key Statistics
Market cap149.69M
Market cap149.69M
Price-Earnings ratio-0.45
Price-Earnings ratio-0.45
Dividend yield—
Dividend yield—
Average volume112.08K
Average volume112.08K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$43.65
52 Week high$43.65
52 Week low$3.74
52 Week low$3.74
Stock Snapshot
Cara Therapeutics(CARA) stock is priced at $15.96, giving the company a market capitalization of 149.69M. It carries a P/E multiple of -0.45.
On 2025-12-15, Cara Therapeutics(CARA) stock opened at —, reached a high of —, and a low of —.
The Cara Therapeutics(CARA)'s current trading volume is 0, compared to an average daily volume of 112.08K.
In the last year, Cara Therapeutics(CARA) shares hit a 52-week high of $43.65 and a 52-week low of $3.74.
In the last year, Cara Therapeutics(CARA) shares hit a 52-week high of $43.65 and a 52-week low of $3.74.
People also own
Based on the portfolios of people who own CARA. This list is generated using Robinhood data, and it’s not a recommendation.